1097-0215/asset/olbannerleft.jpg?v=1&s=45719cd7de57873027993264fcc568b335a8cd56)
1097-0215/asset/olbannerright.jpg?v=1&s=5e0fba63c1309b3036eb9215a0e1e83dd02efd19)
Article
Tumor prevention by a xanthate compound in experimental mouse-skin tumorigenesis
Article first published online: 17 JUL 2006
DOI: 10.1002/ijc.2910430328
Copyright © 1989 Wiley-Liss, Inc., A Wiley Company
1097-0215/asset/cover.gif?v=1&s=9bea5e55449dab2cff7ad3b06277cc9745417a23 "International Journal of Cancer")
Additional Information
How to Cite
Fürstenberger, G., Amtmann, E., Marks, F. and Sauer, G. (1989), Tumor prevention by a xanthate compound in experimental mouse-skin tumorigenesis. Int. J. Cancer, 43: 508–512. doi: 10.1002/ijc.2910430328
Publication History
- Issue published online: 17 JUL 2006
- Article first published online: 17 JUL 2006
- Manuscript Revised: 27 OCT 1988
- Manuscript Received: 8 SEP 1988
- Abstract
- References
- Cited By
Abstract
The antiviral and antitumoral compound tricyclodecan-9-yl-xanthogenate (D609), which is an inhibitor of protein kinase C activation, has been used for tumor prevention in vivo. When applied chronically together with 12-O-tetradecanoylphorbol-13-acetate (TPA) in the classic initiationpromotion mouse-skin model, D609 prevented tumor induction in a dose-dependent manner. At the concentration that inhibited tumor formation by 97%, no toxic effects were detected and the TPA-induced hyperplasia remained unaffected. As D609 failed to prevent the activity of a chronically applied carcinogen, it is concluded that the observed tumor prevention achieved with D609 is tumor-promotion-specific and is not due to killing of tumor cells.